Indaptus Therapeutics, Inc. 8K

Indaptus Therapeutics reported Q2 2026 results, completed a $12 million equity financing, halted Decoy20 clinical development, and initiated a strategic review and new research collaboration in neurological and sleep disorders.

Indaptus Therapeutics, Inc. reported its second quarter and first half 2026 financial results, highlighting an approximately $12.0 million private placement completed on June 17, 2026, significant reductions in research and development and general and administrative expenses, and a strengthened liquidity position with $11.6 million in cash, cash equivalents and short-term investments as of June 30, 2026. The company has halted further enrollment and wound down participation in its Decoy20 clinical studies, leaving it with no active clinical development programs, and is conducting a strategic review of the Decoy platform and broader operations, including potential research collaborations, investments, acquisitions or other business combinations. During the quarter, Indaptus began a research collaboration in neurological disorders and sleep as an extension of its immunotherapy research, while continuing to evaluate capital allocation, strategic fit and potential future growth opportunities under the leadership of CEO and Chairman Junyi Dai.

Filing Facts

CIK

1857044

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-037574

Alert Tier

7